Abstract:
The association between a family history of breast cancer (FHBC) in female first-degree relatives (FDRs) and cancer risk in men has not been evaluated. This study aimed to compare the risks of overall and site-specific cancers in men with and without FHBC. A population-based study was conducted with 3 329 106 men aged ≥40 years who underwent national cancer screening between 2013 and 2014. Men with and without FHBC in their female FDRs were age-matched in a 1:4 ratio. Men without FHBC were defined as those without a family history of any cancer type in their FDRs. Data from 69 124 men with FHBC and 276 496 men without FHBC were analyzed. The mean follow-up period was 4.7 ± 0.9 years. Men with an FHBC in any FDR (mother or sister) had a higher risk of pancreatic, thyroid, prostate and breast cancers than those without an FHBC (adjusted hazard ratios [aHRs] (95% confidence interval [CI]): 1.35 (1.07-1.70), 1.33 (1.12-1.56), 1.28 (1.13-1.44) and 3.03 (1.130-8.17), respectively). Although an FHBC in any one of the FDRs was not associated with overall cancer risk, FHBC in both mother and sibling was a significant risk factor for overall cancer (aHR: 1.69, 95% CI:1.11-2.57) and increased the risk of thyroid cancer by 3.41-fold (95% CI: 1.10-10.61). FHBC in the mother or sister was a significant risk factor for pancreatic, thyroid, prostate and breast cancers in men; therefore, men with FHBC may require more careful BRCA1/2 mutation-related cancer surveillance.
摘要:
女性一级亲属(FDRs)的乳腺癌家族史(FHBC)与男性癌症风险之间的关系尚未得到评估。这项研究旨在比较有和没有FHBC的男性整体和特定部位癌症的风险。一项基于人群的研究是对3329106名年龄≥40岁的男性进行的,他们在2013年至2014年期间接受了国家癌症筛查。在女性FDR中有和没有FHBC的男性以1:4的比例进行年龄匹配。没有FHBC的男性被定义为在其FDR中没有任何癌症类型的家族史的男性。分析了来自69124名FHBC男性和276496名无FHBC男性的数据。平均随访时间为4.7±0.9年。在任何FDR(母亲或姐妹)中都有FHBC的男性患胰腺的风险较高,甲状腺,前列腺癌和乳腺癌比那些没有FHBC(调整的风险比[aHRs](95%置信区间[CI]):1.35(1.07-1.70),1.33(1.12-1.56),1.28(1.13-1.44)和3.03(1.130-8.17),分别)。尽管FHBC在任何一个FDR中都与总体癌症风险无关,母亲和兄弟姐妹的FHBC是总体癌症的重要危险因素(aHR:1.69,95%CI:1.11-2.57),并使甲状腺癌的风险增加3.41倍(95%CI:1.10-10.61)。母亲或姐妹的FHBC是胰腺的重要危险因素,甲状腺,男性的前列腺癌和乳腺癌;因此,FHBC患者可能需要更仔细的BRCA1/2突变相关癌症监测.